All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: HLX15
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Investigational New Drug (IND) application of the Company’s daratumumab biosimilar HLX15 (a recombinant anti-CD38 fully human monoclonal antibody injection) to be used in the treatment of multiple myeloma has been accepted by the National Medical Products Administration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Relmacabtagene autoleucel
Therapeutic Area: Oncology Product Name: Relma-cel
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering November 03, 2020
Details:
Net proceeds from the offering will support the ongoing R&D of other candidates, such as JWCAR-129, JWATM-203, JWATM-204 and Nex-G. The firm will also set aside 16% of the proceeds to license promising assets to expand its pipeline.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MOR210,Checkpoint inhibitor
Therapeutic Area: Oncology Product Name: TJ210
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: MorphoSys
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
Oral presentation will highlight the potent anti-tumor effects demonstrated by TJ210, a novel antibody that blocks C5aR by binding to a unique epitope.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TCRT-ESO-A2
Therapeutic Area: Oncology Product Name: TCRT-ESO-A2
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Axis Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 13, 2020
Details:
Axis Therapeutics and PharmaEssentia will collaborate to conduct an initial clinical study of Axis Therapeutics’ TCRT-ESO-A2 therapy, targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients, and to manufacture the investigational products, in Taiwan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Humanized Claudin18.2 monoclonal antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2020
Details:
Per the development and manufacturing agreement between HJB and Mabspace Bioscience, HJB provided one-stop shop end-to-end CMC package for the Claudin18.2 antibody.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TST001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Details:
Through bioprocess engineering, TST001 is produced with reduced fucosylation and results in significant enhancement in its ADCC inducing activity against Claudin 18.2 expressing tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GC007g
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2020
Details:
The company plans to initiate a phase 1 clinical study in patients with CD19 positive relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) in Q2, 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Taletrectinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
Details:
The first Phase 2 trial will enroll first-and second-line Non-Small Cell Lung Cancer (NSCLC) patients with ROS1 mutations and is designed as an open-label, single-arm, multi-center study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TST001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2020
Details:
TST001 is the first program developed by Transcenta since merger and it took less than 12 months from the identification of preclinical candidate to IND filing.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
